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INTRODUCTION
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a leading cause of cancer morbidity and mortality worldwide with 841,000 new cases and more than 781,000 deaths worldwide in 2018 (1, 2) ; however, despite recent advances in drug development, the outcome for patients with advanced HCC remains poor. Currently approved treatments for HCC in the first-line setting include the multikinase inhibitors sorafenib and lenvatinib. Second-line treatments include the multikinase inhibitors cabozantinib and regorafenib, the anti-VEGF antibody ramucirumab, and the anti-PD1 antibodies nivolumab and pembrolizumab (3).
Although anti-PD1 antibodies are associated with encouraging response durations, most patients do not achieve an objective response. With these available treatments, median progression-free survival (PFS) and overall survival (OS) remain in the ranges of 3 to 7 months and 9 to 13 months, respectively (4) (5) (6) (7) (8) (9) (10) . Thus, there is a critical unmet need for improved novel treatments for HCC.
Emerging data implicate fibroblast growth factor (FGF) 19 as a potential HCC driver and suggest its receptor, the tyrosine kinase FGF receptor 4 (FGFR4), as a novel therapeutic target.
FGF19 normally functions as an ileum-derived postprandial hormone that regulates bile acid synthesis and hepatocyte proliferation via signaling through FGFR4 and co-receptor klotho-β (KLB) (11). However, several studies demonstrated aberrant FGF19 expression in a subset of HCC, potentially implicating FGF19 as a driver of hepatocarcinogenesis (12, 13) . FGF19 overexpression in patients with HCC occurs via genomic amplification of the FGF19/CCND1 locus on chromosome 11q13.3 (~6% of cases) (13) (14) (15) or via epigenetic mechanisms that upregulate FGF19 mRNA/protein (~23% of cases) (16) . In either case, aberrant expression of FGF19 may create an autocrine/paracrine signaling loop in which the ligand binds to FGFR4 and KLB and initiates downstream signaling that promotes HCC proliferation and survival.
Preclinical data support this by showing that ectopic FGF19 expression in vitro promotes HCC proliferation, and transgenic FGF19 expression in mice causes HCC (17, 18) . Targeting FGFR4 with antibodies (19) or small molecule inhibitors (20) attenuates tumor growth in HCC preclinical models, demonstrating the therapeutic potential of this pathway. In a recent study, FGF19 amplification was independently associated with shorter survival and a higher risk of recurrence in patients with HCC and was correlated with poor prognostic factors such as high α-fetoprotein and microvascular invasion (21) .
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Author Manuscript Published OnlineFirst on October 1, 2019; DOI: 10.1158/2159-8290. We developed fisogatinib (BLU-554), a potent and highly selective oral FGFR4 inhibitor optimized for clinical use, and an accompanying immunohistochemistry (IHC) assay to detect aberrant FGF19 expression for use as a potential marker of pathway activation. A phase I firstin-human trial in patients with advanced HCC was conducted to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of fisogatinib and to define the clinical utility of FGF19 IHC as a predictive marker of response.
RESULTS

Fisogatinib Selectively Inhibits FGFR4
Fisogatinib was designed to be a potent, highly selective, small-molecule inhibitor of FGFR4 ( Fig. 1A) . Fisogatinib covalently binds a unique cysteine residue found in FGFR4 (Cys 552;
Supplementary Figure S1A ), thereby conferring a very high degree of selectivity for FGFR4 over other FGFR family members (22) and across the kinome (Fig. 1B) . This selectivity and potent inhibition of FGFR4 were particularly notable when compared with sorafenib, regorafenib, and the pan-FGFR inhibitor, BGJ398, which inhibit a broader range of targets across the kinome ( Fig. 1B) . Fisogatinib also has a high affinity for FGFR4 that is approximately 100-fold higher than its affinity for FGFR1 and almost 1000-fold higher than its affinity for FGFR2 and FGFR3 (22) . Fisogatinib dose-dependently blocked the downstream signaling of FGFR4 in Hep3B cells that were further activated with exogenous FGF19 and in MDA-MB-453 cells with mutated and constitutively active FGFR4 ( Supplementary Fig. S1B and C) (23) . Conversely, fisogatinib did not affect the downstream components of FGFR1 in the lung carcinoma cell line DMS114 when stimulated with FGF2, further confirming the selectivity of this compound ( Supplementary Fig.   S1D ).
To assess the potential utility of FGF19 IHC expression as a marker of pathway activation, we examined the activity of fisogatinib in FGF19 IHC-positive and IHC-negative HCC xenografts. Fisogatinib induced potent, dose-dependent tumor regressions in FGF19 IHCpositive xenografts (Fig. 1C ). By contrast, FGF19-negative tumor lines were resistant to fisogatinib treatment ( Supplementary Fig. S2A and B) . Fisogatinib activity was independent of the level of IHC positivity and was comparable in models with (Hep3B) and without (LIX-066) FGF19 genomic amplification. Tumor regressions were more pronounced with fisogatinib than with sorafenib ( Fig. 1C ). 
FGF19 IHC as a Biomarker for Patient Selection
Because there is consistent expression of FGFR4 and KLB in normal liver and HCC samples ( Supplementary Fig. S3A and B), we focused our diagnostic efforts on the variable expression of FGF19 in HCC. IHC was selected because it requires limited amounts of tissue, is available worldwide, and has the capacity to generate reliable and reproducible results with quick assay turnaround times. A central laboratory assay was developed for clinical trial use, and staining of ≥ 1% of cells was chosen as an initial positivity cutoff based on concordance with FGF19 mRNA expression ( Fig. 2A ). Using this assay, we demonstrated FGF19 expression in a subset of HCC tissues but not in adjacent normal liver ( Fig. 2B ). Of 395 samples tested, 27% were positive for FGF19 staining ≥ 1% above baseline. FGF19 positivity by IHC was well correlated with FGF19 mRNA levels ( Fig. 2A ).
Patient Population and Disposition
This first-in-human study used a 3+3 dose-escalation followed by a maximum tolerated dose (MTD) dose-expansion design ( Supplementary Fig. S4A ). Additional patients could be enrolled to receive dose levels that were declared tolerable. Once-daily (QD) and twice-daily (BID) schedules were explored. For dose escalations, FGF19 tumor expression was assessed retrospectively. For dose expansion, FGF19 tumor expression was assessed prospectively to enroll FGF19 IHC-positive and FGF19 IHC-negative cohorts. A total of 115 patients were enrolled in the study ( Supplementary Table S1 ). Most patients (90%) were on their second or later line of therapy; the median number of prior therapies in the total population was 1 (range, 0-5). On the QD schedule, 106 patients (25 patients in dose escalation; 81 patients in dose expansion), most of whom had been previously treated with sorafenib (85%), were enrolled ( Supplementary Fig. S4A ). In the QD dose escalation phase, patients were treated with 140 mg (n = 3), 280 mg (n = 3), 420 mg, (n = 6), 600 mg (n = 6), or 900 mg (n = 7); the starting dose was 140 mg. After completion of the QD dose escalation, a BID schedule was explored; the starting dose was 200 mg BID (400 mg total daily dose, n = 6), which was escalated to 300 mg BID (600 mg total daily dose, n = 3).
Of all 115 patients enrolled in the study, 63% were positive for FGF19 by IHC. A subset of 53 patients with FGF19-positive tumors by IHC who had available tissue was assessed for FGFR4 and KLB mRNA expression. Importantly, essentially all (n = 51, 96%) FGF19-positive patients in this study also showed FGFR4 and KLB expression by RNA sequencing ( Supplementary Fig. S4B ), confirming FGFR4 pathway integrity. Most patients had metastatic disease and had previously been treated with surgery, transarterial chemoembolization, and systemic therapy, such as sorafenib or other multikinase inhibitors (Table 1) . Infections from hepatitis B virus or hepatitis C virus were the most common HCC etiologies. Patients with FGF19 IHC-positive tumors were more likely to have α-fetoprotein (AFP) levels ≥ 400 ng/mL (P = 0.002) and trended towards being more likely to have macrovascular invasion (P = 0.13) than patients with FGF19 IHC-negative tumors, indicating that FGF19 positivity was correlated with poor prognostic factors, in line with a previous study (21) .
Patients in the QD cohorts remained on treatment for a median of 2.1 months (range, 0.2-15.2 months), and patients in the BID cohorts remained on treatment for a median of 2.1 months (range, 0.2-19.6 months). At the time of the data cutoff, 5 patients (5%) continued treatment on the QD dosing schedule and none continued treatment on the BID dosing schedule. The most common reasons for discontinuing treatment in the total population were progressive disease (75%) and adverse events (AEs, 13%; Supplementary Table S2 ).
Safety
In the QD dose-escalation phase, no dose-limiting toxicities (DLTs) were observed in patients after 1 cycle of fisogatinib with doses of 140 to 600 mg. In the 900-mg cohort, 2 DLTs (1 case of grade 3 abdominal pain and 1 case of grade 3 fatigue lasting > 7 days) were observed ( Supplementary Table S3 ). Therefore, 600 mg was considered the MTD and was selected for the dose expansion phase.
In the BID dose escalation, no DLTs were observed in the initial 3 patients enrolled in Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on October 1, 2019; DOI: 10.1158/2159-8290.CD-19-0555 increased, blood bilirubin increased, diarrhea, and pyrexia (n = 1 each). The majority (53%) of treatment-related AEs in the QD cohorts were grade 1 or 2. The most common treatmentrelated AEs in patients treated with QD fisogatinib were diarrhea (74%), nausea (42%), and vomiting (35%), which are expected on-target toxicities related to enhanced bile acid secretion (Table 2 ). These AEs were manageable with supportive care and dose interruption or reduction. Grade ≥ 3 treatment-related AEs occurred in 46 patients overall (43%), with the most common being elevated aspartate aminotransferase (16/106, 15%) and alanine aminotransferase (12/106, 11%) levels. Grade ≥ 3 diarrhea, vomiting, and nausea occurred in 8 (8%), 4 (4%), and 2 (2%) patients, respectively. Serious AEs of any grade occurred in 46 patients (43%) in the QD dosing cohorts, with the most common being disease progression (n = 5), hepatic failure (n = 4), anemia (n = 3), elevated blood bilirubin (n = 3), pyrexia (n = 3), and vomiting (n = 3). There were no treatment-related deaths in the BID or QD dosing groups. Treatment-emergent grade 5 AEs were experienced by 10 patients in the QD dosing cohorts, and none were related to fisogatinib ( Supplementary Table S6 ). Additional treatment-emergent AEs for the QD dosing cohorts are listed in Supplementary Table S6 .
Pharmacokinetics and Pharmacodynamics in the Dose-Escalation Phase
To assess fisogatinib exposure in patients, blood was collected before dosing with fisogatinib and at prespecified time points following dosing on cycle 1, day 1 (C1D1) and on cycle 1, day 15 (C1D15). Following administration of single oral doses of fisogatinibranging from 140 to 900 mg QD, the median time to peak concentration (T max ) ranged from 1.5 to 2 hours post-dosing (Fig.   3A ). The mean plasma elimination half-life (t 1/2 ) of fisogatinib was 16.5 hours. Systemic exposure of fisogatinib increased in a dose-dependent manner after a single dose on C1D1 and repeat dosing on C1D15. There was no significant drug accumulation (accumulation ratio [Rac] ≤ 1.5) after repeat dosing of fisogatinib, consistent with the observed half-life. At C1D15, the steady state geometric mean (%CV; n) for the maximum plasma concentration (C max ) and area under the curve (AUC o-τ ) of fisogatinib at the 600-mg QD dose was 8925 ng/mL (33.5%; n = 70) and 91,742 h×ng/mL (42.0%; n = 64), respectively. This exposure to fisogatinib was within the expected therapeutic range based on nonclinical data in xenograft models, supporting 600 mg QD as the recommended phase II dose.
FGFR4 pathway activation by FGF19 promotes bile acid production from cholesterol (24) . To study the effects of fisogatinib on FGFR4 pathway activity, fasting blood samples were collected from patients and assessed for plasma or serum cholesterol, bile acid precursors, and FGF19. As would be expected from FGFR4 pathway inhibition, levels of plasma cholesterol were dose-dependently reduced after treatment, while levels of bile acid increased after treatment, reflecting derepression of bile acid synthesis. In addition, levels of serum FGF19 dose-dependently increased due to release of negative feedback ( Fig. 3B-D) .
Clinical Activity
Across 106 patients treated with QD dosing, 98 were evaluable for response assessments per RECIST v1.1 with measurable disease at baseline and at least 1 post-baseline radiographic response assessment. Sixty-six patients with FGF19-positive tumors were evaluable for response, and the overall response rate (ORR) in this population was 17% (11 of 66 patients), with 1 complete response (CR; 2%) and 10 partial responses (PRs, 15%; Fig. 4A , Table 3 ).
Three patients remained in response at the time of data cutoff. One patient experienced a PR in the 280-mg cohort, 2 in the 420-mg cohort, and 7 in the 600-mg cohort; the patient who experienced a CR was in the 600-mg cohort. Responses were observed across a wide range of FGF19 IHC positivity ( Supplementary Table S7 ). Eight of the 11 responders had received prior sorafenib. Radiographic tumor reduction and response per RECIST 1.1 were observed in 41% of patients with (FGF19 FISH-positive) and without (FGF19 FISH-negative) FGF19 genomic amplification. Response typically occurred at the first radiographic assessment (2 months); the median duration of response (DOR) for responding patients with FGF19-positive tumors was 5.3 months (95% CI, 3.7 months-not reached; Fig. 4B, Table 3 ), and the median progression-free survival (PFS) was 3.3 months (95% CI, 2.1−3.7 months). Eight of the responding patients had responses > 6 months ( Fig. 4C ).
Of 34 patients who had FGF19-negative tumors or an unknown FGF19 status (n = 29 FGF19 negative; n = 5 unknown), 32 were evaluable for response assessments. Per RECIST v1.1, the ORR in these patients was 0% (0 of 32 patients), with 16 patients (50%) having stable disease and 16 patients (50%) having progressive disease as a best response ( Effective treatment options for advanced HCC are limited compared with other tumor types, and there have been few biomarker-driven targeted therapies identified to date (25) . Although the FGF19/FGFR4 pathway has been implicated in hepatocarcinogenesis for more than a decade, no approach has demonstrated the oncogenic importance of this pathway in human HCC to date (12, 17, 18) . This phase I study with the highly potent and selective FGFR4 inhibitor fisogatinib clinically validates the therapeutic potential of the FGF19-FGFR4 pathway by demonstrating for the first time that FGFR4 inhibition is tolerable and efficacious in advanced (26); therefore, these agents did not advance in clinical testing. Our study demonstrates the feasibility and tolerability of targeting the FGF19-FGF4 pathway with a smallmolecule approach. Notably, fisogatinib was tolerable across multiple dose levels that modulated the FGFR4 pathway and had antitumor activity. As expected, the most common AEs were on-target toxicities related to enhanced bile acid synthesis, including nausea, vomiting, and diarrhea. At the 600 mg QD recommended phase II dose, these events were readily managed with antiemetics and supportive care. The BID schedule had more prominent ontarget toxicity and was less well tolerated, perhaps related to more continuous FGFR4 inhibition.
In contrast with pan-FGFR4 inhibitors (20, 27) , no hyperphosphatemia was observed with fisogatinib treatment across all dose levels, confirming the exquisite selectivity of fisogatinib for FGFR4. Overall, these data indicate that selective FGFR4 inhibition via a small-molecule approach is feasible and tolerable; however, it is dependent on dose and schedule. (15) . Interrogation of these pathways in tumor and circulating tumor DNA is feasible using next-generation sequencing. Additional studies regarding this are underway, and the results of these investigations may further refine patient selection.
In conclusion, the findings from this study of fisogatinib demonstrate for the first time that safety, and antitumor activity data support a continuous QD dosing schedule for fisogatinib for further clinical investigation. This study illustrates that FGFR4 signaling is targetable by small molecules for effective, biomarker-driven treatment of HCC. Based on these data and recent data suggesting enhanced efficacy with combinations of targeted therapies and checkpoint inhibitors (29) (30) (31) , we are pursuing further development of fisogatinib in FGF19-positive patients both as a monotherapy and combination with immunotherapy. 
METHODS
Study Design and Patients
Endpoints
The primary objectives were to determine the MTD and recommended phase II dose of fisogatinib and to assess safety and tolerability. Secondary objectives included characterization of the PK and PD profiles, definition of FGF19 status in tumor tissue via IHC and FISH, and assessment of preliminary evidence of antitumor activity per RECIST v1.1.
Assessments
Patients without documented disease progression were followed for disease assessment approximately every 3 months until disease progression, the start of another antineoplastic therapy, or death. AEs were assessed for intensity according to the National Cancer Institute's The following PK parameters of fisogatinib were assessed as appropriate following single-dose administration and at steady state: C max ; T max ; AUC from 0 to 24 hours; t 1/2 ; apparent oral clearance (CL/F); apparent volume of distribution (V z /F); and Rac. The following PD parameters were assessed: changes in blood including, but not limited to, changes in blood FGF19 (part 1 only); cholesterol; bile acid precursors (eg, 7α-hydroxy-4-cholesten-3-one [cycle 4], part 1 only); AFP; and changes in tumor Ki-67 and cleaved caspase-3 levels.
IHC Assay Development
An assay using an FGF19 rabbit monoclonal antibody (clone SP268, Roche Tissue Diagnostics, Tucson, AZ) was optimized for use as a fully automated IHC assay on the BenchMark ULTRA (Roche Tissue Diagnostics) staining platform using the OptiView DAB IHC Detection Kit and OptiView Amplification Kit (Roche Tissue Diagnostics). The assay was optimized for detection of FGF19 protein expression in formalin-fixed, paraffin-embedded HCC tissue. Parameters evaluated during optimization included antibody concentration, antibody diluent, antigen retrieval method, antibody incubation conditions, and counterstain conditions. In addition, signal amplification using the OptiView Amplification Kit (Roche Tissue Diagnostics) was tested to evaluate its efficacy in visualizing specific signals. The optimal conditions for tumor cell staining in HCC tissue on the BenchMark ULTRA instrument are outlined in Supplementary Table S8 .
Briefly, antigen retrieval was undertaken for 16 minutes, the primary antibody was applied for 16 minutes at 36°C, and amplification was conducted for 8 minutes amplifier/8 minutes multimer.
Samples were counterstained for 8 minutes with hematoxylin II and post-counterstained for 8 minutes.
Statistical Analyses
Descriptive analyses were used to characterize safety, PK, PD, and efficacy. The Kaplan-Meier method was used to estimate medians for DOR and PFS. The 95% CIs for DOR and PFS were 
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